MetaCap

Fulcrum Therapeutics (FULC) vs Greenwich LifeSciences (GLSI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Greenwich LifeSciences (GLSI) has outperformed Fulcrum Therapeutics (FULC) over the past year, gaining 136.2% versus a loss of 67.3%. Over five years, GLSI leads with a -41.8% price change compared with -75.5% for FULC. Greenwich LifeSciences is the larger company by market cap ($282.6 million vs $281.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FULC-67.32%GLSI+136.20%
+331%+120%-91%
Nov 21, 20251 yearNov 20, 2026
FULC-78.47%GLSI-44.75%
+45%-24%-92%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FULC versus GLSI key metrics
MetricFULCGLSI
Share price$3.69$19.25
Market cap$281.85M$282.56M
1-day change-0.54%-2.73%
YTD return-67.37%-8.38%
1-year return-67.32%+136.20%
5-year return-75.50%-41.84%
EPS (TTM)$-1.04$-1.63
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-74.88M$-19.36M
52-week high$15.74$34.10
52-week low$2.83$7.78
Distance from 52-week high-76.56%-43.55%
Analyst consensusholdstrong_buy
Avg. price target upside-0.54%+198.70%
Average volume1.37M160.76K
Shares outstanding76.38M14.68M
Employees55—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GLSI has outperformed FULC by 203.5 percentage points over the past year.

About Fulcrum Therapeutics

FULC stock →

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees

About Greenwich LifeSciences

GLSI stock →

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.

Health Care · Biotechnology: Pharmaceutical Preparations

FULC vs GLSI FAQ

Which is bigger, Fulcrum Therapeutics or Greenwich LifeSciences?

Greenwich LifeSciences (GLSI) is larger, with a market capitalization of $282.56M compared with $281.85M for Fulcrum Therapeutics (FULC).

Which stock has performed better over the past year, FULC or GLSI?

GLSI returned +136.20% over the past 12 months, compared with -67.32% for FULC (price return, excluding dividends). Past performance does not predict future results.

Are Fulcrum Therapeutics and Greenwich LifeSciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons